ArticleCancer medicine2025
Preoperative Inflammatory Status and Postoperative Morbidity in Patients With Primary Retroperitoneal Sarcoma.
Article in Cancer medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Consensus Guidelines on Perioperative Care in Primary Retroperitoneal Sarcoma Surgery.Annals of surgical oncology · 2026Article
- Complications and outcomes after definitive surgery for traumatic high-energy pelvic fractures.European journal of orthopaedic surgery & traumatology : orthopedie traumatologie · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe role of preoperative inflammatory markers in predicting postoperative outcomes has been investigated in different types of cancer. However, little is known about retroperitoneal sarcoma (RPS). This study aimed to evaluate the association between preoperative inflammatory status and major postoperative morbidity in patients undergoing RPS surgery.
methodsData on patients undergoing surgery for primary RPS between 2008 and 2022 at three specialist sarcoma centers were analyzed. The preoperative inflammatory status was evaluated, assessing the C-reactive protein (CRP) value, the neutrophil/lymphocyte ratio (NLR), and the platelet/lymphocyte ratio (PLR). The primary outcome was 90-day major postoperative morbidity. The best-balanced cutoff values to apply in the uni- and multivariable analysis were calculated using a receiver operating characteristic (ROC) curve analysis.
resultsData were available for 239 patients. Major postoperative complications occurred in 52 of 235 patients (22.1%). Increased median values of CRP, NLR, and PLR were significantly higher in patients with dedifferentiated liposarcoma (DDLPS) (p < 0.001). As such, further analysis focused only on this specific histotype. On multivariable analysis, after adjusting for potential confounders, the association between increasing CRP and NLR with 90-day major postoperative morbidity remained significant, with an OR of 2.96 (95% CI: 1.03-8.49, p = 0.044) for CRP > 61 mg/L, and with an OR of 4.69 (1.55-14.20, p = 0.006) for NLR > 4.85.
conclusionElevated preoperative levels of CRP and NLR are independently associated with major postoperative morbidity in patients affected by primary retroperitoneal DDLPS. These findings may help decision-making and optimize perioperative management in these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.